Lyra Therapeutics, Inc. (LYRA)
Largest Insider Buys in Sector
LYRA Stock Price History Chart
LYRA Stock Performance
About Lyra Therapeutics, Inc.
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase …
Insider Activity of Lyra Therapeutics, Inc.
Over the last 12 months, insiders at Lyra Therapeutics, Inc. have bought $74,095 and sold $0 worth of Lyra Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Lyra Therapeutics, Inc. have bought $17.31M and sold $2.24M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Waksal Harlan (Executive Chair) — $74,095.
The last purchase of 25,000 shares for transaction amount of $74,095 was made by Waksal Harlan (Executive Chair) on 2023‑11‑10.
List of Insider Buy and Sell Transactions, Lyra Therapeutics, Inc.
| 2023-11-10 | Executive Chair | 25,000 0.0498% | $2.96 | $74,095 | +11.37% | |||
| 2023-05-31 | 3.61M 9.5077% | $2.49 | $9M | +49.03% | ||||
| 2023-05-31 | 10 percent owner | 1.81M 4.6346% | $2.43 | $4.39M | +49.03% | |||
| 2023-05-31 | 10 percent owner | 1.2M 3.0898% | $2.43 | $2.92M | +49.03% | |||
| 2023-05-31 | 1.81M 4.6346% | $2.43 | $4.39M | +49.03% | ||||
| 2022-06-10 | 4,000 0.0119% | $5.05 | $20,200 | -35.30% | ||||
| 2022-05-13 | 328 0.001% | $5.00 | $1,640 | -19.36% | ||||
| 2022-04-12 | 5.92M 11.8975% | $4.22 | $25M | -21.89% | ||||
| 2022-04-12 | 1.08M 2.1626% | $4.22 | $4.54M | -21.89% | ||||
| 2022-04-12 | 765,010 1.5364% | $4.22 | $3.23M | -21.89% | ||||
| 2022-04-12 | Executive Chair | 236,966 0.4759% | $4.22 | $999,997 | -21.89% | |||
| 2021-06-17 | director | 3,500 0.0267% | $8.97 | $31,395 | -36.57% | |||
| 2020-12-16 | director | 1,025 0.0118% | $9.72 | $9,963 | -14.25% | |||
| 2020-05-05 | Sale | 10 percent owner | 33,818 0.3972% | $16.00 | $541,088 | -28.92% | ||
| 2020-05-05 | Sale | 10 percent owner | 48,366 0.568% | $16.00 | $773,856 | -28.92% | ||
| 2020-05-05 | Sale | 48,366 0.568% | $16.00 | $773,856 | -28.92% | |||
| 2020-05-05 | Sale | 10 percent owner | 9,674 0.1136% | $16.00 | $154,784 | -28.92% | ||
| 2020-05-05 | 1.25M 7.3399% | $8.00 | $10M | -28.92% | ||||
| 2020-05-05 | 10 percent owner | 62,500 0.734% | $16.00 | $1M | -28.92% | |||
| 2020-05-05 | 10 percent owner | 500,000 5.8719% | $16.00 | $8M | -28.92% |
Insider Historical Profitability
| Waksal Harlan | Executive Chair | 261966 0.4002% | $0.27 | 2 | 0 | <0.0001% |
| PERCEPTIVE ADVISORS LLC | 11469117 17.5217% | $0.27 | 2 | 0 | +10.05% | |
| EDELMAN JOSEPH | 7858285 12.0053% | $0.27 | 1 | 0 | <0.0001% | |
| ANDERSON EDWARD T | 2521745 3.8525% | $0.27 | 3 | 1 | <0.0001% | |
| NBVM GP, LLC | 10 percent owner | 2521745 3.8525% | $0.27 | 3 | 1 | +23.05% |
Institutional Investor Ownership
| Perceptive Advisors | $79.35M | 20.93 | 12.76M | 0% | +$0 | 0.05 | |
| Citadel Advisors LLC | $26.99M | 7.12 | 4.34M | +51.65% | +$9.19M | 0.02 | |
| Nantahala Capital Management Llc | $17.55M | 4.63 | 2.82M | -30.35% | -$7.65M | 0.82 | |
| Samsara Biocapital Llc | $17.29M | 4.56 | 2.78M | 0% | +$0 | 2.7 | |
| Point72 Asset Management | $17.06M | 4.5 | 2.74M | -8.59% | -$1.6M | 0.03 |